Serum leucine-rich α-2 glycoprotein 1 predicts 10-year mortality and vascular events in coronary angiography patients.

Background And Aims: Leucine-rich α-2 glycoprotein 1 (LRG1) is a pro-inflammatory signaling molecule that is highly upregulated in various pathological conditions, including cardiovascular disease. We tested the hypothesis whether LRG1 levels are associated with incident all-cause mortality, vascular mortality, and major adverse cardiovascular events (MACE) in coronary angiography patients.

Methods: A total of 695 patients referred for elective coronary angiography were included in the study.

Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1q.

Treatment of multiple myeloma has advanced tremendously with the approval of anti-CD38 antibodies. Their efficacy is impressive but still controversial in the 1q amplification subgroup (amp1q). This retrospective study aims to provide real-world data.

Evaluation of Circulating Glypican-4 in Patients with ESKD.

Key Points: Glypican-4 (GPC4) levels were strongly elevated in incident dialysis patients compared with individuals without evidence of kidney disease. Circulating GPC4 was significantly correlated with various parameters linked to adverse conditions commonly present in incident dialysis patients. No association was found between GPC4 and all-cause mortality in incident dialysis patients.

Evaluation of circulating glypican 4 as a novel biomarker in disease - A comprehensive review.

Glypican 4 (GPC4), a member of the cell surface heparan sulfate proteoglycan family, plays a crucial role in regulating various cell signaling and developmental processes. Its ability to be released from the cell surface into the bloodstream through shedding makes it a promising blood-based biomarker in health and disease. In this context, circulating GPC4 has been initially proposed as an insulin-sensitizing adipokine being linked with various conditions of insulin resistance.

Three decades of glucose-lowering therapy in patients at high cardiovascular risk - A real-world analysis.

Aim: Over recent years, therapy options and strategies for type 2 diabetes mellitus (T2DM) have developed substantially. This study investigated glucose-lowering treatment in patients with high cardiovascular risk over three decades.

Materials And Methods: A total of 2158 patients undergoing elective coronary angiography at a tertiary care hospital in Europe were included in three sequential observational studies (OS): OS1 (1999-2000; n = 672), OS2 (2005-2008; n = 1005) and OS3 (2022-2023; n = 481).